Home › NDC Lookup › Ingredients › Capsaicin › 70000-0549-01
Leader Capsaicin Pain Relief Cream .1 g/100g Cream, 1 tube — NDC 70000-0549-01 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

Leader Capsaicin Pain Relief Cream .1 g/100g Cream, 1 tube — NDC 70000-0549-1 (Billing 70000-0549-01)

by Cardinal Health 110 dba LEADER · 1 TUBE in 1 BOX / 42.5 g in 1 TUBE

This is a package of 1 tube of Leader Capsaicin Pain Relief Cream .1 g/100g Cream from Cardinal Health 110 dba LEADER, marketed since May 2020 and currently FDA-listed; retail pharmacies pay about $0.2068 per g (NADAC). It is this product's only package size.

NDC 70000-0549-01
🏷️ FDA NDC (as labeled) 70000-0549-1 billing pads the package segment with a zero
OTC On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

NDC database record

One package, one record: these facts belong to NDC 70000-0549-1 alone.

Record
FDA NDC Directory package listing · Human OTC drug
Code segments
70000 labeler · 0549 product · 1 package
Package marketed since
May 11, 2020
Sample package
No — commercial package
Listing certified through
Dec 31, 2026
Barcode (UPC-A, from the NDC)
3 7000005491 5
Medicaid fills, this package
2,368 prescriptions in the last four reported quarters
FDA record last changed
Jul 24, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 70000-0549-1
Product NDC 70000-0549
11-digit billing NDC 70000054901
NCPDP billing unit GM — per gram (weight)
RxCUI 646333
UNII S07O44R1ZM
Application # M017
SPL Set ID a5620709-0fed-4979-e053-2a95a90ac654
DEA schedule Non-controlled
Marketing category OTC MONOGRAPH DRUG
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2020-05-11
Route TOPICAL
Dosage form CREAM
Substance CAPSAICIN

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 90850025003735
GPI class Capsaicin Pain Relief
GCN Seq No 058057
GCN 23373
HICL code 002577
Ingredient (HICL) Capsaicin
HIC1 code L
Therapeutic class — broad (HIC1) Skin/Subcutaneous Tissue
HIC2 code L6
Therapeutic class — intermediate (HIC2) Irritants
HIC3 code L6A
Therapeutic class — specific (HIC3) Irritants/Counter-Irritants
AHFS code 84:92.00.00
AHFS class Skin And Mucous Membrane Agents, Misc.
FDB label name CAPSAICIN 0.1% CREAM
FDB brand name Capsaicin
Legend status O — Over-the-counter (OTC) drug or device
Quick answers
  • GSN (GCN sequence number): 058057
  • GCN: 23373
  • GPI-14 (Medi-Span): 90850025003735
  • HICL (First Databank): 002577
  • AHFS class code: 84:92.00.00
  • RxCUI (RxNorm): 646333
Why two NDCs? The FDA registers this code as 70000-0549-1 — a 5-4-1 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the package segment → 70000-0549-01. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Capsaicin and similar agents class.

Drug family (ATC) Capsaicin and similar agents, Other local anesthetics
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name CAPSAICIN 0.1% CREAM Ingredient Capsaicin
📗 Our plain-language guide HelloPharmacist
  • Yes, completely normal — and it actually means the medicine is working. Capsaicin activates the same pain-sensing receptors in your skin that respond to heat and spicy food. That b...
  • Why does capsaicin burn when I put it on? Is that normal?
  • For most OTC creams and ointments, you can apply up to 3 to 4 times a day. For OTC patches, apply to clean, dry skin and remove after no more than 8 hours — again, up to 3 to 4 tim...
  • How often should I apply capsaicin cream or use the patch?
📖 Read our full Capsaicin guide →

Supplement & herbal interactions

Some supplements/herbs that may interact with Capsaicin (prescription drug) — tap one for details:

Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer gPer package
Retail pharmacies payNADAC · weekly $0.207 $8.79 / 42.5 g
Medicaid paysCMS SDUD · 12 mo $0.3552 $15.10 / 42.5 g
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
NADAC price history (per g) — tap or hover for the price & month
Dec 2023 Jan 2026 May 2026 Sep 2026 $0.207 $0.176
▲ Up 5% over the last 13 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
70000-0549-01 You're viewing this Main listing 1 TUBE in 1 BOX / 42.5 g in 1 TUBE 2020-05-11 — Active

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Rugby Capsaicin Cream .1 g/100g 00536-1264-56 Rugby 1 tube $0.207 — Availability likely —
Capsaicin .1 g/100g 50268-0198-42 AvPAK 1 tube $0.207 — Availability likely —
Leader Capsaicin Pain Relief Cream .1 g/100gthis 70000-0549-01 Cardinal 1 tube $0.207 — Availability likely —
Walgreens Arthritis Pain Relief Capsaicin Analgesic 1 mg/g 00363-0837-01 Walgreen 1 tube — — FDA listed —
Heat Pain Relief .1 g/100g 00363-6263-07 Walgreen 1 applicator — — FDA listed —
Earths Care Arthritis .1 g/100g 24286-1559-02 DLC 1 tube — — FDA listed —
Capzasin HP Arthritis Pain Relief .001 g/g 41167-7514-02 Chattem, 1 tube — — FDA listed —
Capsaicin .001 g/g 50268-0197-56 AvPAK 1 tube — — FDA listed —
Capsaicin 0.1 Percent .1 g/100g 50488-1060-06 Alexso, 60 g — — FDA listed —
Capsaicin 0.1% Cream 1 mg/g 59088-0242-08 Puretek 120 g — — FDA listed —
Cvs Capsaicin .1 g/100g 59779-0381-42 CVS 1 tube — — FDA listed —
Capsaicin HP Arthritis Pain Relief .1 g/100g 69375-0006-60 Nationwide 1 tube — — FDA listed —
Capsaicin Cream .1 g/100g 69396-0103-02 Trifecta 1 tube — — FDA listed —
Capzix .001 g/g 72847-0316-20 Toprail 1 tube — — FDA listed —
Capsaicin Cream .1 g/100g 73141-0558-02 A2A 1 tube — — FDA listed —
Capsaicin .1 g/100g 76420-0753-42 Asclemed 1 tube — — FDA listed —
Toast Screamin Hot .1 g/100g 78983-0102-05 IDEAZ, 148 g — — FDA listed —
Capsaicin Cream .1 g/100g 81533-0200-15 Noble 1 tube — — FDA listed —
NeroCare Capsaicin Neuropathy Relief Cream .1 g/100g 84066-0108-01 Guangzhou 100 g — — FDA listed —
Dr. Luke Capsaicin Cream Extra Strength .1 g/100g 87147-0003-01 DANOUS 114 g — — Discontinued —
Easment advanced absorption cream .12 g/120g 87352-0001-01 Easment 120 g — — FDA listed —
High Potency Pain Relief .1 g/100g 87773-0001-01 Xiamen 114 g — — FDA listed —
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2020
On the market since
May 2020
📍
2026
Currently FDA-listed
6 years listed
🔒
·
No generic listed yet
brand only
ℹ️No FDA-approved generic found

We did not find an FDA-approved generic match for this exact strength, form and route.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

🧪 Avoiding an ingredient? See Capsaicin inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerCardinal Health 110 dba LEADER
FDA applicationM017 (OTC MONOGRAPH DRUG)
Labeler code70000
First marketedMay 2020
Product typeHuman Otc Drug
Portfolio11 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

FDA label — Drug Facts FDA SPL

The complete FDA label for this product — the official Drug Facts labeling, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage 22 words ▾

Uses For the temporary relief of minor aches and pains of muscles and joints associated with: Arthritis Simple Backache Strains Sprains Bruises

⏱️ Dosage and Administration 47 words ▾

Directions Adults and Children over 18 years: Apply to affected area Massage into the painful area until thoroughly absorbed Repeat as necessary but not more than 3 to 4 times daily WASH HANDS WITH SOAP AND WATER AFTER APPLYING Children 18 years and younger: Ask a doctor

⚠️ Warnings 101 words ▾

Warnings For external use only: TEST FIRST ON SMALL AREA OF SKIN. When using this product: Use only as directed Do not apply to wounds, damaged, broken or irritated sin Do not use if you are allergic to capsicum or chili peppers Avoid contact with the eyes or mucous membranes A slight burning sensation may occur upon application, but generally disappears in several days If severe burning occurs, discontinue use Do not expose the treated area to heat or direct sunlight Do not bandage Do not use with heating pad Do not use at the same time as other topical analgesics

📦 Storage and Handling 8 words ▾

Other Information Store at room temperature 15°-30°F (59°-86°F)

🧪 Active Ingredient 4 words ▾

Active Ingredient Capsaicin 0.1%

🧪 Inactive Ingredients 20 words ▾

Inactive Ingredients Aloe barbadensis leaf juice, Ethylparaben, Glycerin, Clyceryl monostearate, Mineral Oil, Octadecyl alcohol, Petrolatum, Purified Water, Sodium lauryl Sulfate

🎯 Purpose 3 words ▾

Purpose Topical Analgesic

📄 Stop Use and Ask a Doctor If 35 words ▾

Stop Use and Ask Doctor Stop Use and Ask Doctor if: Condition worsens Symptoms persist for more than 7 days or clear up and occur again within a few days Redness is present irritation develops

🤰 If Pregnant or Breast-Feeding 10 words ▾

If Pregnant or Breast Feeding Ask a doctor before use

📄 Keep Out of Reach of Children 21 words ▾

Keep Out of the Reach of Children If swallowed, get medical help or contact a Poison Control Center (1-800-222-1222) right away.

📄 Questions or Comments 53 words ▾

Questions 1 (800) 200- 6313 Distributed by Cardinal Health Dublin, Ohio 43017 This product is not manufactured or distrubuted by Chattem Inc. owner of registered trademark Capzasin HP, 2020 Cardinal Health Leader and Logos are trademarks of Cardinal Health. All other marks are the property of their respective owners www.myleader.com Made in China

📄 Package Label / Principal Display Panel 3 words ▾

LEADER CAPSAICIN CREAM

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
2.4K
Units reimbursed last 4 qtrs
109.3K
Gross reimbursed last 4 qtrs
$38.8K
Avg / prescription
$16.40
Avg / unit
$0.3552
Latest quarter Q1 2026
594Rx
Medicaid pays / g
$0.3552
gross reimbursed
vs
NADAC / g
$0.2068
acquisition cost
=
Spread
+$0.1484
+72% vs cost
What Medicaid paid per g (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
72% FFS 28% MCO
Fee-for-service · 1,696 Rx Managed care · 672 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: no data reported WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: 2,890 units · 50.4 per 100k residents MN Wisconsin: no data reported WI Michigan: no data reported MI New York: 64,105 units · 328 per 100k residents NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: no data reported OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: 9,903 units · 78.9 per 100k residents IL Indiana: no data reported IN Ohio: 10,636 units · 90.3 per 100k residents OH Pennsylvania: 9,945 units · 76.7 per 100k residents PA New Jersey: 10,838 units · 117 per 100k residents NJ Massachusetts: no data reported MA California: no data reported CA Utah: no data reported UT Colorado: no data reported CO Nebraska: no data reported NE Missouri: no data reported MO Kentucky: no data reported KY West Virginia: no data reported WV Virginia: no data reported VA Maryland: no data reported MD Connecticut: 978 units · 27.0 per 100k residents CT Rhode Island: no data reported RI Arizona: no data reported AZ New Mexico: no data reported NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: no data reported TN North Carolina: no data reported NC South Carolina: no data reported SC Delaware: no data reported DE Oklahoma: no data reported OK Louisiana: no data reported LA Mississippi: no data reported MS Alabama: no data reported AL Georgia: no data reported GA D.C.: no data reported DC Hawaii: no data reported HI Texas: no data reported TX Florida: no data reported FL
Units reimbursed · per 100k residents
27.0328
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 New York 328 /100k
2 New Jersey 117 /100k
3 Ohio 90.3 /100k
4 Illinois 78.9 /100k
5 Pennsylvania 76.7 /100k
6 Minnesota 50.4 /100k
7 Connecticut 27.0 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Capsaicin — the ingredient across all brands.

Top reported reactions

Application Site Pain556
Pain494
Burning Sensation346
Pain In Extremity262
Fatigue234
Application Site Erythema153
Dyspnoea138

Age at onset

Child2
Adolescent4
Adult358
Elderly350

Reporter sex

3,943 reports
Male · 41%
Female · 59%
Unknown · 0%

Serious outcomes

Hospitalization779
Disabling136
Life-threatening80
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 317 0
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.